FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
64Cu-ATSM PET/MRI was initially developed to image hypoxia, where the agent was trapped in hypoxic cells. This demonstrated efficiency in predicting outcomes in several solid tumors including cancers of the head and neck, lung, rectum and cervix. 64Cu-ATSM uptake has been correlated with MRI features of clinically significant disease on both T2 and diffusion weighted MR imaging. Additionally, the potential benefit of less transitional zone but more seminal vesical, bladder (but not lumenal), or nodal uptake has been noted. ATSM signal uniformity compared to mpMRI has been seen in areas of extracapsular extension.
The expanding selection of prostate cancer radiotracer pharmaceuticals may be overwhelming, but selecting the optimal tracer may have potential benefit for evaluation of tumor burden with treatment implications.
Presented by: Joseph Ippolito, MD, PhD, Washington University School of Medicine in St. Louis
Written by: David B. Cahn, DO, MBS, @dbcahn, Fox Chase Cancer Center, at the 18th Annual Meeting of the Society of Urologic Oncology, November 29-December 1, 2017 – Washington, DC